Jump to content

JOIN THE DISCUSSION!

Want to join the discussions?

Sign up for a free membership! 

If you are a member already, log in!

(lost your password? reset it here)

99nicu.org 99nicu.org

EBNEO Commentary: Does the effect of hydrocortisone in preterm infants depend on the baseline risk of BPD?


EBNEO

Recommended Posts

F7LbsFlWQAA7ImQ.jpeg

Article of the Month by Gentle SJ, Rysavy MA, Li L, et al. on Heterogeneity of Treatment Effects of Hydrocortisone by Risk of Bronchopulmonary Dysplasia or Death Among Extremely Preterm Infants in the National Institute of Child Health and Human Development Neonatal Research Network Trial: A Secondary Analysis of a Randomized Clinical Trial published in the JAMA Network Open reviewed by Nicolas Bamat and Timothy Nelin from Children's Hospital of Philadelphia.

Read here!

 
Also listen it discussed on The Incubator Podcast!

Incubator:https://buff.ly/3EUq61t

#neotwitter #neoEBM #EBNEOreviews

#ActaPaediatrica
#JAMA
 
Acta Paediatrica commentary by Timothy Nelin and Nicolas Bamat: 
 
"BPD remains the most common chronic morbidity of preterm birth despite advances in the survival of preterm infants.12 Prior studies demonstrated postnatal corticosteroid effects vary with infants' baseline BPD risk, motivating the current study to investigate if an infant's baseline predicted risk for BPD or death modifies the effect of hydrocortisone.34 Unlike prior metaregression analyses comparing data between trials, Gentle et al. compared data among infants enrolled in the NICHD NRN Hydrocortisone Trial and did not identify statistically significant differences in the effects of hydrocortisone on death, BPD, or neurodevelopmental impairment when analysed by infants' baseline risk for BPD or death.

The findings published by Gentle et al. must be considered within the context of a subpopulation of extremely preterm infants with high baseline illness severity and may not generalise to broader preterm populations. The current data do not examine whether the baseline risk for BPD or death modifies the effect of hydrocortisone in all extremely preterm infants as infants in the NICHD NRN Hydrocortisone Trial carried a high risk for developing BPD based on the physiologic definition5–83.4% of infants in the hydrocortisone group and 86.4% of infants in the placebo group developed the composite outcome of death or BPD.6Prior studies investigating postnatal hydrocortisone found that 49% and 71% of infants receiving placebo died or developed BPD, with lower rates of death or BPD among hydrocortisone exposed infants.78 Infants in those studies were exposed to hydrocortisone within 24 h of birth and at a median of 10 days, respectively. Therefore, infants in the NICHD NRN Hydrocortisone Trial represent a subset of extremely preterm infants with higher overall risk for death or BPD and were exposed to hydrocortisone at an older age.

While no significant interaction of hydrocortisone treatment and baseline risk for BPD or death with the primary efficacy outcome was noted, close investigation suggests a trend towards a lower comparative relative risk for the development of grade 2 or 3 BPD in infants in the highest quartile of BPD or death risk (RR 0.94; 95% CI 0.81, 1.09) compared to infants in the lowest quartile of risk (RR 1.13; 95% CI 0.82, 1.55). The risk difference estimates for these quartiles highlight the clinical relevance of these trends: an estimate of a 5% higherabsolute risk for BPD or death among infants exposed to hydrocortisone in the lowest risk quartile and a 5% lower absolute risk among infants exposed to hydrocortisone in the highest risk quartile. These data suggest that infants with higher risks of BPD or death may comparatively benefit from postnatal hydrocortisone as administered in this trial, but with too much uncertainty.

In conclusion, among extremely preterm infants enrolled in the NICHD NRN Hydrocortisone Trial, the effect of hydrocortisone was not modified by baseline risk for developing grades 2 or 3 BPD or death. Further research in larger and more representative cohorts of extremely preterm infants would aid in understanding potential differential effects of hydrocortisone exposure among infants with baseline differences in lung disease severity."

 

  • Like 2
  • Upvote 2
Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
×
×
  • Create New...